MedPath

Zoledronic acid

Generic Name
Zoledronic acid
Brand Names
Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
Drug Type
Small Molecule
Chemical Formula
C5H10N2O7P2
CAS Number
118072-93-8
Unique Ingredient Identifier
70HZ18PH24
Background

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
Associated Therapies
Bone Mineral Density

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Phase 1
Not yet recruiting
Conditions
Neuroblastoma
Rhabdomyosarcoma
Synovial Sarcoma
Peripheral Nerve Sheath Tumors
Clear Cell Sarcoma
Alveolar Soft Part Sarcoma
Desmoplastic Small Round Cell Tumor
Chordoma
Rhabdoid Tumor
Epithelioid Sarcoma
Interventions
Device: Miltenyi CliniMACS Prodigy ® system
Drug: Zoledronic acid
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
University of Florida
Target Recruit Count
27
Registration Number
NCT06625190

Romosozumab As an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

Phase 3
Not yet recruiting
Conditions
FHA (Functional Hypothalamic Amenorrhea)
Interventions
First Posted Date
2024-08-01
Last Posted Date
2024-11-21
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
114
Registration Number
NCT06533865

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1
Not yet recruiting
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions
First Posted Date
2024-04-18
Last Posted Date
2024-11-19
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
152
Registration Number
NCT06374459
Locations
🇺🇸

The University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Phase 3
Not yet recruiting
Conditions
Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Interventions
First Posted Date
2024-01-24
Last Posted Date
2024-01-24
Lead Sponsor
Shanghai JMT-Bio Inc.
Target Recruit Count
1360
Registration Number
NCT06221072

Sequential Therapies After Osteoanabolic Treatment

Recruiting
Conditions
Osteoporosis, Postmenopausal
Interventions
First Posted Date
2023-12-11
Last Posted Date
2023-12-15
Lead Sponsor
424 General Military Hospital
Target Recruit Count
150
Registration Number
NCT06164795
Locations
🇩🇪

Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

🇬🇷

251 Airforce & VA General Hospital, Athens, Greece

🇬🇷

424 General Military Hospital, Thessaloniki, Greece

and more 6 locations

FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA

Phase 4
Recruiting
Conditions
Trochanteric Fracture of Femur
Osteoporotic Fracture of Femur
Hip Fractures
Bone Density, Low
Interventions
Procedure: OSTEOSYNTHESIS
Drug: Zoledronic acid
Device: CERAMENT BONE VOID FILLER (BVF)
First Posted Date
2023-11-18
Last Posted Date
2023-12-15
Lead Sponsor
Aksaray University
Target Recruit Count
20
Registration Number
NCT06135298
Locations
🇹🇷

Aksaray University Training and Research Hospital, Aksaray, Turkey

The Optimised Use of Romozosumab Study

Phase 4
Recruiting
Conditions
Osteoporosis
Interventions
First Posted Date
2023-09-28
Last Posted Date
2023-10-25
Lead Sponsor
University of Aarhus
Target Recruit Count
270
Registration Number
NCT06059222
Locations
🇩🇰

Department of Endrocinology and Internal Medicine, Aarhus, Denmark

Effect of Zoledronic Acid in Primary Knee Osteoarthritis

Phase 4
Recruiting
Conditions
Primary Osteoarthritis
Interventions
First Posted Date
2023-09-22
Last Posted Date
2023-09-22
Lead Sponsor
Toufiqe-E-Ealahi
Target Recruit Count
92
Registration Number
NCT06051344
Locations
🇧🇩

Department of rheumatology, Dhaka, Shahbag, Bangladesh

HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Phase 3
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Procedure: HAIC
Drug: Zoledronic acid
First Posted Date
2023-05-19
Last Posted Date
2023-05-19
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
264
Registration Number
NCT05866172
Locations
🇨🇳

Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients

Phase 4
Recruiting
Conditions
Hip Fractures
Pneumonia
Interventions
First Posted Date
2023-02-24
Last Posted Date
2024-02-20
Lead Sponsor
The University of Hong Kong
Target Recruit Count
2692
Registration Number
NCT05743179
Locations
🇭🇰

Caritas Medical Centre, Sham Shui Po, Hong Kong

🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

🇭🇰

United Christian Hospital, Kwun Tong, Hong Kong

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath